Insight

Jun 8, 2024, 09:58

Angelo Pirozzi: Circulating immune-related proteins might predict the efficacy of Immune Checkpoint Inhibitors

Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X: .

“92 Circulating-immuno-oncology-related proteins in patients with metastatic PDAC (Pancreatic Ductal Adenocarcinoma) from the CheckPAC trial who responded to radiotherapy +nivolumab ± ipilimumab.

High FASLG (FAS ligand) and Gal-1 lead to higher PFS (progression-free survival)

Circulating immune-related proteins might predict the efficacy of ICIs (Immune Checkpoint Inhibitors).”

Proceed to the article.
Source: Angelo Pirozzi/X

Angelo Pirozzi cancer CheckPAC FASLG Immune checkpoint inhibitors (ICIs) immune-related proteins ipilimumab Mayo Clinic metastatic PDAC nivolumab OncoDaily Oncology pancreatic ductal adenocarcinoma PDAC PFS

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Special Coverage